Ynthetic Hypericin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biopharmaceutical company Soligenix, Inc. (SNGX) announced Monday that the U.S. Food and Drug Administration (FDA) has granted a Type A meeting to discuss the contents of a refusal to file (RTF) letter previously issued regarding the Company's new drug application (NDA) for HyBryte (synthetic hypericin) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer. ....

Drug Administration , Soligenix Inc , More Such Health News , Us Food And Drug Administration , Iopharmaceutical Company Soligenix , Ynthetic Hypericin ,